BDA-366

SKU: orb1300475

Description

BDA-366 is a high-affinity, selective antagonist of the Bcl-2 BH4 domain (Ki = 3.3 nM). It induces a pro-apoptotic conformational change, effectively inhibiting lung cancer cell growth in vitro, and shows potential for apoptosis research in oncology.

Research Area

Cell Biology

Key Properties

• CAS Number: 1909226-00-1
• MW: 423.5
• Purity: 98.61% (May vary between batches)
• Formula: C₂₄H₂₉N₃O₄
• SMILES: N(C[C@H]1CO1)C2=C3C(=C(NC[C@@H](CN(CC)CC)O)C=C2)C(=O)C=4C(C3=O)=CC=CC4
• Target: Bcl-2 Family
• Solubility: Ethanol:5 mg/mL (11.81 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (7.79 mM);DMSO:78 mg/mL (184.18 mM)

Bioactivity

• Target IC50:
  Bcl-2:3.3 nM (Ki)
• In Vitro:
  NSC 228155 promotes transactivation of several RTKs, including ErbB2 and ErbB3, Insulin R and IGF-1 R receptors in the cells. It stimulates dimerization of sEGFR domain II. NSC 228155 can rapidly move across cell membranes and disperse within both cytoplasmic and nuclear compartments. It rapidly generates hydrogen peroxide within cells. NSC 228155 is also a potent inhibitor of KIX-KID interaction(IC50 = 0.36 μM), but it is not particularly selective against CREB-mediated gene transcription in HEK 293T cells.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Bcl2-BH4 domain, Bcl-2 Family, BDA-366, BDA366, BDA 366, Anticancer, Antiapoptotic function, Antitumor, Lung cancer, Inhibitor, inhibit

Compound Identifiers

PubChem CID

91826545